Humalog Mix 25 Kwikpen 100IU


Name: Humalog Mix 25 Kwikpen 100IU
Substance: Insulin Lispro Injection by Eli Lilly
1 Pack: 5 pens x 3ml (100 iu/ml)

SKU: 938 Category:


Release form

Suspension for subcutaneous administration of white color, which exfoliates, forming a white precipitate and a clear colorless or almost colorless supernatant; the precipitate is easily resuspended with gentle shaking. 3 ml each in a cartridge built into the QuickPen ™ syringe pen – 5 syringe pens in a cardboard box.

Injection needles are not included in the package.

pharmachologic effect

A hypoglycemic drug, a combination of fast and medium-acting insulin analogues. Humalog® Mix 25 is a DNA recombinant analogue of human insulin and is a ready-made mixture consisting of insulin lispro solution (a fast-acting analogue of human insulin) and a suspension of insulin lispro protamine (an analogue of human insulin of medium duration).

The main action of insulin lispro is the regulation of glucose metabolism. In addition, it has anabolic and anti-catabolic effects on various body tissues. In muscle tissue, there is an increase in the content of glycogen, fatty acids, glycerol, an increase in protein synthesis and an increase in the consumption of amino acids, but at the same time there is a decrease in glycogenolysis, gluconeogenesis, ketogenesis, lipolysis, protein catabolism and amino acid release.

It has been shown that insulin lispro is equimolar to human insulin, but its action develops faster and lasts for a shorter time. The onset of action of the drug is about 15 minutes, which allows it to be administered immediately before a meal (0-15 minutes before a meal), in comparison with ordinary human insulin. After subcutaneous injection of Humalog Mix 25, a rapid onset of action and an early peak in the activity of insulin lispro are observed. The action profile of insulin lispro protamine is similar to that of regular insulin isophane with a duration of about 15 hours.

Indication for use

Diabetes mellitus requiring insulin therapy.

Methods of administration and doses

The doctor determines the dose individually, depending on the level of glucose in the blood. The insulin administration mode is individual.

The drug should be administered subcutaneously. Intravenous administration of the drug Humalog Mix 25 is contraindicated!

The temperature of the injected drug should be at room temperature.

P / C should be injected into the shoulder, thigh, buttocks, or abdomen. The injection sites should be alternated so that the same site is used no more than 1 time per month. With subcutaneous administration of the drug Humalog, care must be taken to avoid getting the drug into the blood vessel. After injection, do not massage the injection site.

When inserting the cartridge into the insulin delivery device and attaching the needle prior to delivering insulin, strictly follow the manufacturer’s instructions for the insulin delivery device.

At the beginning of treatment, the patient should be trained in injection technique.


  • hypoglycemia;
  • hypersensitivity to drug components.

special instructions

To date, no undesirable effect of insulin lispro on pregnancy or the condition of the fetus and newborn has been identified.

The goal of insulin therapy during pregnancy is to maintain adequate glucose control. The need for insulin usually decreases in the first trimester and increases in the second and third trimesters of pregnancy. During and immediately after childbirth, the need for insulin can drop dramatically.

Women of childbearing age with diabetes mellitus should inform the doctor about the onset or planned pregnancy.

In patients with diabetes mellitus during breastfeeding, it may be necessary to adjust the dose of insulin and / or diet.

The transfer of a patient to another type or preparation of insulin with a different trade name must take place under strict medical supervision. Changes in activity, brand (manufacturer), type (for example, Regular, NPH), species (animal, human, analog of human insulin) and / or method of production (DNA-recombinant insulin or insulin of animal origin) may require dose adjustment …

The use of inadequate doses or discontinuation of treatment, especially in patients with insulin-dependent diabetes mellitus, can lead to hyperglycemia and diabetic ketoacidosis (a condition that potentially threatens the patient’s life).

The need for insulin may decrease with insufficient function of the adrenal glands, pituitary gland or thyroid gland, with renal or hepatic insufficiency. With some diseases or emotional stress, the need for insulin may increase. Insulin dosage adjustments may also be required if you increase exercise or change your usual diet.

During hypoglycemia, the patient may have a decrease in concentration and the speed of psychomotor reactions. This can be dangerous in situations where these abilities are especially needed (for example, driving a car or operating machinery).

Patients should be advised to take precautions to avoid hypoglycemia while driving and operating machinery. This is especially important for patients with mild or absent symptoms, predictors of hypoglycemia, or with frequent development of hypoglycemia. In such cases, the doctor should evaluate the appropriateness of the patient’s driving and operating machinery.

Additional information





, ,